Ilaris and Phenoxybenzamine Hydrochloride

• Generic Name: canakinumab
• Dosage Forms: injection, powder, lyophilized, for solution
• Other Brand Names: Ilaris

Ilaris (canakinumab) is a monoclonal antibody that blocks certain proteins in the body that can affect inflammation and other immune responses. Ilaris is used to treat certain types of periodic fever syndromes, sometimes called auto-inflammatory syndromes.

Periodic fever syndromes are rare and often inherited conditions caused by mutations in certain genes; usually genes that are involved in producing a certain protein or enzyme in the body. People with a periodic fever syndrome have episodes of fever and inflammation without other causes such as infection or virus.

Ilaris is used to treat the following periodic fever syndromes in adults and children who are at least 4 years old:

• Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome
• Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)
• Hyperimmunoglobulin D Syndrome (HIDS), also called Mevalonate Kinase Deficiency (MKD)
• Familial Mediterranean Fever (FMF)

Ilaris is also used to treat Sudden Juvenile Idiopathic Arthritis (SJIA) in children who are at least 2 years old.

• Generic Name: phenoxybenzamine
• Dosage Forms: n.a.
• Other Brand Names: Dibenzyline

Prevention or treatment of paroxysmal hypertension and sweating in patients with pheochromocytoma.

Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of hypertension caused by pheochromocytoma notamenable to surgery.

Used in conjunction with a β-adrenergic blocking agent (propranolol) to control symptoms from excessive β-receptor stimulation in patients with inoperable or metastatic pheochromocytoma or to control tachycardia prior to or during pheochromocytomectomy. (See General under Dosage and Administration.)

Has been used as adjunctive therapy in the treatment of peripheral vasospastic disorders associated with increased α-adrenergic activity (e.g., Raynaud’s syndrome, acrocyanosis, and frostbite sequelae) but efficacy in the treatment of peripheral vascular disease is not established.

Phenoxybenzamine should not be used in diseases affecting large blood vessels.

Has been used in the treatment of micturition disorders resulting from neurogenic bladder, functional outlet obstruction, or partial prostatic obstruction.

Has been used for the prevention and treatment of acute postoperative urinary retention, including that associated with the use of epidural morphine.